Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fulcrum Therapeutics Inc
(NQ:
FULC
)
7.550
-0.250 (-3.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fulcrum Therapeutics Inc
< Previous
1
2
3
4
5
Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors
May 01, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
May 01, 2023
From
The Schall Law Firm
Via
Business Wire
FULCRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm
April 28, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
April 28, 2023
From
The Schall Law Firm
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fulcrum Therapeutics, Inc. (FULC)
April 28, 2023
From
Robbins LLP
Via
Business Wire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces CFO Resignation
April 05, 2023
Rajavelu to continue supporting Fulcrum in a consulting capacity
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ:FULC Shareholder Notice: Investigation over Possible Securities Laws Violations by Fulcrum Therapeutics, Inc.
March 14, 2023
San Diego, CA -- (SBWIRE) -- 03/14/2023 -- Fulcrum Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
March 09, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
March 06, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
FULCRUM ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulcrum Therapeutics, Inc. on Behalf of Fulcrum Stockholders and Encourages Investors to Contact the Firm
March 03, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fulcrum Therapeutics, Inc. (FULC) Investigation
March 02, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
March 02, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
March 02, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
March 01, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
March 01, 2023
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
March 01, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
February 24, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
February 08, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
January 17, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
January 17, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
January 04, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces CEO Transition
January 04, 2023
Robert J. Gould, Ph.D., former president and founding chief executive officer of Fulcrum, is appointed as interim CEO as Bryan Stuart departs to pursue other opportunities
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
December 01, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 11, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
November 08, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.